View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
June 4, 2020

ASCO 2020: DESTINY-Gastric01 trial reveals positive outlook for the treatment of HER2 positive gastric cancer patients with Enhertu

By Victoria Smith

At the virtual ASCO 2020 conference, an update on DESTINY-Gastric01 Phase II trial provided a positive outlook for the future therapy of gastric cancer patients with the drug Enhertu (trastuzumab deruxtecan).

Enhertu is an antibody-drug conjugate made up of the HER-2 targeting trastuzumab antibody attached to a topoisomerase inhibitor payload. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena